CD274 and cancer: Of 17 patients who received systemic cancer treatment, 13 received chemotherapy, two received targeted therapy, and two patients received an immune checkpoint inhibitor, a PD-L1 inhibitor, with or without an anti-CTLA antibody (Table 3).